CAS 1204317-86-1|Edasalonexent

Introduction：Basic information about CAS 1204317-86-1|Edasalonexent, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Edasalonexent BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Edasalonexent
CAS Number	1204317-86-1	Molecular Weight	490.677
Density	1.0±0.1 g/cm3	Boiling Point	716.8±60.0 °C at 760 mmHg
Molecular Formula	C₃₁H₄₂N₂O₃	Melting Point	/
MSDS	/	Flash Point	387.3±32.9 °C

Names

Name	edasalonexent
Synonym	More Synonyms

Edasalonexent BiologicalActivity

Description	Edasalonexent is an orally bioavailable NF-κB inhibitor.
Related Catalog	Research Areas >>Metabolic Disease
Target	NF-κB[1]
In Vitro	Edasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever duchenne muscular dystrophy (DMD) model[2].
In Vivo	The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury[1].
Animal Admin	Mice[1] Male mdx or WT mice are used. Drug treatment protocols entail feeding individually housed mice a specialty control chow or chow containing either CAT-1041 or Edasalonexent (0.75% w/w) ad libitum starting at 4 weeks of age. Average drug consumption typically ranges between 0.75 and 1 mg/g body weight per day. The 24-hour plasma exposure at this dosage is 450ng hr/mL for Edasalonexent[1].
References	[1]. Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341. [2]. Donovan JM, et al. A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.

Chemical & Physical Properties

Density	1.0±0.1 g/cm3
Boiling Point	716.8±60.0 °C at 760 mmHg
Molecular Formula	C₃₁H₄₂N₂O₃
Molecular Weight	490.677
Flash Point	387.3±32.9 °C
Exact Mass	490.319550
LogP	7.31
Vapour Pressure	0.0±2.4 mmHg at 25°C
Index of Refraction	1.554
Storage condition	2-8℃

Synonyms

AF3Z6434KS

Benzamide, 2-hydroxy-N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-1-oxo-4,7,10,13,16,19-docosahexaen-1-yl]amino]ethyl]-

edasalonexent

N-{2-[(4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoylamino]ethyl}-2-hydroxybenzamide

Recommended......